Those with a diagnosis of this condition must receive appropriate treatment. What is a person’s life expectancy with psoriatic arthritis? PsA does not usually affect life expectancy, but a ...
When compared with other biologic therapies, patients with psoriasis receiving IL-23 inhibitors had a lower risk for inflammatory arthritis or psoriatic arthritis development.
The Food and Drug Administration (FDA) has expanded the approval of Bimzelx ® (bimekizumab-bkzx) to include 3 new indications. In addition to plaque psoriasis, Bimzelx, a humanized interleukin-17A and ...
UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with ...